Tumor Necrosis Factor–Blocking Agents in Polymyalgia Rheumatica and Giant Cell Arteritis

  1. Raashid A. Luqmani, DM
  1. From University of Oxford, Oxford OX3 7LD, United Kingdom.

    IN RESPONSE:

    I am grateful to Drs. Salvarani and Hunder for raising the issue that their studies of infliximab in polymyalgia rheumatica and GCA were not designed to test a small treatment effect of the agent above that achieved from corticosteroid alone. If there is only a small treatment effect, a cost–benefit analysis is likely to conclude that infliximab does not have a clinically or …

    « Previous | Next Article »Table of Contents